复发4级IDH野生型胶质瘤的挽救治疗:BRAIN登记真实世界分析
本研究基于BRAIN登记数据库,纳入2019年9月至2024年1月确诊的275例复发4级IDH野生型胶质瘤患者,分析挽救治疗模式。结果显示全身治疗最常用(85%),其中67%接受单药贝伐珠单抗;29%行再切除,仅9例接受再放疗。再切除与单纯全身治疗相比,进展后生存无显著差异(p=0.242)。
要点
- 全身治疗是复发胶质母细胞瘤最常用的挽救方式,贝伐珠单抗单药占多数。
- 再切除患者更年轻、体能状态更好且多在一线治疗后复发,但校正后生存无优势。
- 再放疗使用极少,仅9例,两次放疗中位间隔15个月。
核心结论
- 全身治疗是复发胶质母细胞瘤最常用的挽救治疗,主要为贝伐珠单抗。
- 再切除与单纯全身治疗相比,进展后生存无显著差异(p=0.242)。
- 再放疗在挽救治疗中极少使用。
研究设计与样本
- 基于BRAIN登记数据库的真实世界分析,纳入2019年9月至2024年1月确诊的4级IDH野生型胶质瘤患者。
- 仅纳入有明确复发/进展日期后接受挽救治疗的患者,共275例。
- 采用Kaplan-Meier法计算生存,Cox回归进行多因素分析。
主要发现
- 275例患者中位年龄61岁(范围23-88),复发时56%为ECOG 0-1。
- 中位进展时间7.6个月,65%在一线治疗期间复发/进展。
- 全身治疗占85%,其中67%接受单药贝伐珠单抗,该亚组结局与临床试验数据相似。
- 29%患者行再切除,其中58%术后接受全身治疗;再切除患者更年轻(p=0.02)、体能状态更好(p=0.006)、更可能在一线治疗完成后复发(p=0.001)。
- 仅9例接受再放疗,两次放疗中位间隔15个月;中位进展后生存(PPS)为9.5个月。
临床怎么用
- 复发4级IDH野生型胶质瘤以全身治疗为主,贝伐珠单抗单药是常见选择。
- 再切除宜用于年轻、体能状态好且一线治疗后进展的患者,但需告知生存获益不明确。
- 再放疗在真实世界中使用极少,决策需个体化。
局限性
- 真实世界登记数据,治疗选择受患者因素影响,存在选择偏倚。
- 再放疗等亚组样本量小,统计效能有限。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The prognosis for patients with glioblastoma after failure of first-line therapy is poor. Despite this, the standard of care for patients with recurrent disease is not well-defined. Here we report on the use of salvage therapies in glioblastoma using real-world data. METHODS: Data were extracted from the BRAIN Registry for patients diagnosed with glioblastoma (Grade 4, IDH wild-type) between 09/2019 and 01/2024. Only patients who received salvage therapies following a documented date of recurrence/progression were included. Relevant descriptive and intergroup statistics were used, with survival calculated using Kaplan-Meier and Cox regression used for multivariate analyses. RESULTS: 275 patients were identified. Median age was 61 (range:23-88) years, with 56% being ECOG 0-1 at recurrence. Median time to progression was 7.6 months with 65% recurring/progressing during first-line therapy. Systemic therapy (85%) was most utilised with 67% receiving single-agent bevacizumab. Outcomes in this subgroup were similar to clinical trial data. 29% patients underwent re-resection with 58% of these then receiving systemic treatment. Compared with no surgery, patients who underwent re-resection were younger (p = 0.02), of better performance status (p = 0.006) and more likely to have recurred post completing first-line therapy (p = 0.001). Few patients (n = 9) received re-irradiation with median of 15 months between radiation events. Median post-progression survival (PPS) was 9.5 months. After adjustment for confounders, there was no difference in PPS for patients who underwent re-resection versus systemic therapy alone (p = 0.242). The survival differences observed between treatment modalities likely reflect patient factors influencing treatment selection and were impacted by small subgroup sizes. CONCLUSION: Systemic therapy is most utilised in the salvage setting, predominantly bevacizumab. Certain patient characteristics were associated with re-resection. Re-irradiation was rarely used. CLINICAL TRIAL NUMBER: ACTRN12618001959268.
引用
- Sanderson E, Drummond K, Dowling A, et al. Salvage therapies for recurrent grade 4 IDH-wildtype glioma: a BRAIN Registry analysis of real-world treatment patterns. J Neurooncol. 2026. PMID: 42493681. doi:10.1007/s11060-026-05717-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。